In an attempt to identify the antigens expressed on human myeloid leukemia cells, two murine monoclonal antibodies (mAb) designated as MCS-1 (isotype; IgG3) and MCS-2 (IgGi) were raised. MCS-1 reacted with peripheral blood granulocytes, but not with monocytes, whereas MCS-2 reacted with both granulocytes and monocytes. The incidence of MCS-1 and MCS-2 reactivity with the cells from a total of 121 patients with various type of leukemias was as follows: 25/46 (54%) and 39/47 (83%) in acute myeloblastic leukemia and acute monoblastic leukemia, 8/16 and 16/16 in chronic myeloid leukemia in blastic crisis (CML-BC) of myeloid type, 0/7 and 2/7 in CML-BC of lymphoid type, 0/26 and 2/32 in acute lymphoblastic leukemia (ALL), 7/7 and 7/7 in chronic phase of CML, respectively. Two cases of MCS-2 positive ALL had a Philadelphia chromosome marker (Phl). In contrast, neither MCS-1 nor MCS-2 reacted with lymphocytes or any of leukemic and non-leukemic lymphoid cell lines tested. These results indicate that MCS-1 and MCS-2 mAb recognized two different differentiation antigens expressed on granulocytes and monocytes. These mAb would be useful reagents to determine differentiation antigens on the cells in granulocyte and monocyte lineage.
. Mononuclear cells were isolated by FicollHypaque discontinuous density gradient centrifugation. In all cases, the percentage of leukemic blasts in the isolated mononuclear cell population was more than 80%.
Thymocytes were prepared by mincing and filtrating through a stainless steel wire mesh from the thymuses which were obtained from the patients under corrective cardiac surgery who do not have hematological disorders. Informed consents were obtained for each case and the use of left-over cells after diagnostic procedure was approved by the Institutional Review Committee.
Peripheral blood leukocytes in the heparinized venous blood obtained from the healthy volunteers were analyzed without separation of the cells by using immunofluorescence method and under FACScan(R) flow cytometry (Becton Dickinson Immunocytometry Systems, San Jose, CA) after lysing the erythrocytes.
Immunological marker analysis
The leukemia cells were characterized by multiple immunological markers as previously described (Minowada et al. 1982) . Briefly, E-, EA-and EAC-resetting cells were counted by using sheep erythrocytes (E), bovine erythrocyte-IgG antibody complex (EA), and bovine erythrocyte-IgM antibody-complement complex (EAC), respectively. Surface membrane immunoglobulins (SmIg) and cytoplasmic immunoglobulins (Cylg) were detected by direct immuno uorescence using fluorescein-isothiocyanate (FITC) conjugated goat anti-human immunoglob-uli light or heavy chain specific reagents (Cappel, Cochranville, PA). Human T-cell antigen (T-Ag) (Tsubota et al. 1977) , 33) antigen (Koyama et al. 1977) , and antigen associated primarily with common form of ALL (CALL) (Koshiba et al. 1978) were assessed by indirect membrane immunofluorescence using respective polyclonal rabbit antibody reagents and FITC-conjugated goat anti-rabbit IgG reagent. A number of selected mAb were also used to substitute or/and supplement the results of polyclonal antibodies.
Preparation of marine mAb
Female BALB/cCR mice (RPMI West Seneca Laboratory, West Seneca, NY) were immunized intravenously with 107 viable cells of ML-3 or HL-60 five times at weekly intervals. Murine mAb were generated by a standard method as reported previously (Kohler and Milstein, 1975) . The culture supernatants of hybridomas containing antibody against the cells of immunized cell lines (ML-3 or HL-60) were positively selected by indirect membrane immunofluorescence.
Next, the culture supernatants of hybridomas showing antibody activity against the cells of three T cell lines (MOLT-4, HPB-ALL, and RPMI-8402), three non-T non-B cell lines (Reh, KM-3, and NALM-16), or three B cell lines (BALL-1, Ramos, and RPMI-8057) were identified and eliminated from the subsequent study.
Membrane immunofluorescence
A mAb designated as MCS-1 generated from the ML-3 immunized mice and another mAb designated as MCS-2 generated from the HL-60 immunized mice were thus selected, respectively. Immunoglobulin isotypes of MCS-1 and MCS-2 were murine IgG3 and IgGl, respectively, determined by Ouchterlony double immunodiffusion method using relevant goat anti-mouse isotype specific antibodies. Surface markers were examined by indirect or direct immunofluorescence method as reported (Sagawa et al. 1995) . The stained cells were analyzed by a UV microscope or FACScan(R) flow cytometry (Becton Dickinson Immunocytometry Systems, San Jose, CA). Peripheral blood leukocytes were first stained in the form of heparinized whole blood by immunofluorescence method, and then fluorescein profile of each leukocyte population was analyzed under FACScan(R) flow cytometry after lysing the erythrocytes. Majority of cases in the fresh-uncultured cell population even in a monoclonal leukemia, purity of one type of cell population was never at 100% owing the presence of residual normal cells. Furthermore, myeloid leukemia cells present often in themselves heterogeneity that is characterized by morphological criteria. Therefore, if only a fraction of cell population was stained, 30% or greater than 30% was taken as positive.
Immunoprecipitation
Immunoprecipitation of cell surface antigens recognized by MCS-1 and MCS-2 was performed using ML-3 cells and HL-60 cells as cell source, respectively, by the standard method as reported previously (Sakai et al. 1987) . There is specific immunoprecipitation of a polypeptide of 130,000 dalton apparent molecular weight by MCS-2 and MY7. A band at 100,000 dalton apparent molecular weight is also immunoprecipitated by MCS-2. The numbers at the right-hand side indicate the markers of molecular weights (X1,000 dalton). The result of immunoprecipitation of HL-60 cell lysate by the MCS-2 mAb is shown in Fig. 2 . Specific bands of apparent molecular weight 100,000 dalton and 130,000 dalton were present when MCS-2 was used for the immunoprecipitation (Fig. 2, lane B) . Parallel preparations using MY7 (CD13) (Griffin et al. 1981) revealed an identical band at apparent molecular weight of 130,000 dalton, but the band at 100,000 dalton was not observed (Fig. 2, lane C) . Attempts were also made to immunoprecipitate the molecules recognized by MCS-1 antibody using ML-3 cells as cell source. However, no immunoprecipitations were obtained by the above mentioned method (data not shown).
Discussion
The peripheral blood granulocytes were stained with both MCS-1 and MCS-2, but monocytes were stained with only MCS-2. Neither lymphocytes nor thymocytes were stained with MCS-2. These results indicate a rather narrow reactivity repertoire of MCS-1, which seems to be confined to granulocyte lineage, in contrast to that of MCS-2, which seems to react broadly with the cells of both granulocyte and monocyte lineages.
Among 47 cases of AML and AMoL tested, MCS-1 reacted to 54% (25/46) and MCS-2 reacted to 83% (39/47), respectively. At any rate, the MCS-2 antigen has a broader distribution than the MCS-1 AGAINST MYELOID LEUKEMIA 183 antigen among the leukemia cells tested. In CML-BC cases of myeloid type, MCS-reacted to blasts from 8 out of 16 cases, and MCS-2 all of them. The blasts from 5 out of 7 cases of CML-BC of lymphoid type showed no reactivity with either MCS-1 or MCS-2. It should be noted, however, that the remaining 2 cases of CML-BC of lymphoid type reacted with MCS-2 but not MCS-1. In these 2 cases of CML-BC of lymphoid type and 2 cases of Phl positive ALL, the same leukemia cells expressed both common ALL antigen and MCS-2 antigen. The leukemia cells in some CML-BC of lymphoid type or Phl positive ALL cases may arise from a point in differentiation more closely related to myeloid lineage than those in common non-T non-B cell ALL. Such cases demonstrate the potential value of MCS-2 antibody as a predictive marker for Phl anomaly in cases of ALL.
The non-reactivity of MCS-1 or MCS-2 with the cells of the 50 non-myeloid lines appears to fulfill the prerequisite for their specificity within the nonlymphoid lineage. The non-reactivity of MCS-1 or MCS-2 with the cells from an erythroid precursor cell line (K562) (Lozzio and Lozzio, 1975; Andersson et al. 1979 ) may further support indirectly its properties of erythroid lineage distinct from myeloid lineage. Several reports have already dealt with mAb detecting myelomonocyte antigens using various antigen sources including myeloid leukemia cell line cells, fresh leukemia cells, or normal peripheral blood cells (Bread et al. 1980; Raff et al. 1980; Ugolini et al. 1980; Civin et al. 1981; Griffin et al. 1981; Maj dic et al. 1981; Zola et al. 1981 (Griffin et al. 1981 ) mAb bind a polypeptide of 130,000 dalton apparent molecular weight. It may be assumed that they bind to different epitopes because MCS-2 also binds to a polypeptide of 100,000 dalton molecular weight.
The present study describes two anti-myeloid mAb, MCS-1 and MCS-2, that were subsequently determined as CD 15 mAb and CD 13 mAb, respectively, in the International Workshop on Human Leukocyte Differentiation Antigens. The availability of anti-myeloid-monocyte cell antibodies such as MCS-1 and MCS-2 described in this study will provide further insight into the understanding of myeloid cell biology and classification of myeloid malignancies. 
